These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 37735703)

  • 1. Chromone-embedded peptidomimetics and furopyrimidines as highly potent SARS-CoV-2 infection inhibitors: docking and MD simulation study.
    Shakibay Senobari Z; Masoumian Hosseini M; Teimouri MB; Rezayan AH; Samarghandian S; Hekmat A
    BMC Res Notes; 2023 Sep; 16(1):224. PubMed ID: 37735703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Some Flavolignans as Potent Sars-Cov-2 Inhibitors
    Cetin A
    Curr Comput Aided Drug Des; 2022; 18(5):337-346. PubMed ID: 35975852
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Maurya AK; Mishra N
    J Biomol Struct Dyn; 2021 Nov; 39(18):7306-7321. PubMed ID: 32835632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pea eggplant (
    Govender N; Zulkifli NS; Badrul Hisham NF; Ab Ghani NS; Mohamed-Hussein ZA
    PeerJ; 2022; 10():e14168. PubMed ID: 36518265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of Iminosugars as Antiviral Agents against SARS-CoV-2 Main Protease: Inhibitor Design and Optimization, Molecular Docking, and Molecular Dynamics Studies to Explore Potential Inhibitory Effect of 1-Deoxynojirmycin Series.
    Miglani V; Sharma P; Kumar Narula A
    Curr Comput Aided Drug Des; 2023 Aug; ():. PubMed ID: 37612857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of Effective Therapeutic Molecule from Natural Sources against Coronavirus Protease.
    Fadaka AO; Sibuyi NRS; Martin DR; Klein A; Madiehe A; Meyer M
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and molecular dynamics simulation studies of quinoline derivatives as protease inhibitors against SARS-CoV-2.
    Singh VK; Chaurasia H; Kumari P; Som A; Mishra R; Srivastava R; Naaz F; Singh A; Singh RK
    J Biomol Struct Dyn; 2022; 40(21):10519-10542. PubMed ID: 34253149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unveiling the Inhibitory Potentials of Peptidomimetic Azanitriles and Pyridyl Esters towards SARS-CoV-2 Main Protease: A Molecular Modelling Investigation.
    Mushebenge AG; Ugbaja SC; Mtambo SE; Ntombela T; Metu JI; Babayemi O; Chima JI; Appiah-Kubi P; Odugbemi AI; Ntuli ML; Khan R; Kumalo HM
    Molecules; 2023 Mar; 28(6):. PubMed ID: 36985614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the inhibitory potential of novel piperidine-derivatives against main protease (M
    Rafique A; Muhammad S; Iqbal J; Al-Sehemi AG; Alshahrani MY; Ayub K; Gilani MA
    J Mol Liq; 2023 Jul; 382():121904. PubMed ID: 37151376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated bioinformatics-cheminformatics approach toward locating pseudo-potential antiviral marine alkaloids against SARS-CoV-2-Mpro.
    Swain SS; Singh SR; Sahoo A; Panda PK; Hussain T; Pati S
    Proteins; 2022 Sep; 90(9):1617-1633. PubMed ID: 35384056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation.
    Choudhary MI; Shaikh M; Tul-Wahab A; Ur-Rahman A
    PLoS One; 2020; 15(7):e0235030. PubMed ID: 32706783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based computational screening of 470 natural quercetin derivatives for identification of SARS-CoV-2 M
    Kakhar Umar A; Zothantluanga JH; Luckanagul JA; Limpikirati P; Sriwidodo S
    PeerJ; 2023; 11():e14915. PubMed ID: 36935912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 25 (S)-Hydroxycholesterol acts as a possible dual enzymatic inhibitor of SARS-CoV-2 M
    Alzahrani FA; Alkarim SA; Hawsawi YM; Abdulaal WH; Albiheyri R; Kurdi B; Alguridi H; El-Magd MA
    J Biomol Struct Dyn; 2023 Jul; 41(10):4744-4755. PubMed ID: 35510619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of polyphenols from
    Ghosh R; Chakraborty A; Biswas A; Chowdhuri S
    J Biomol Struct Dyn; 2021 Oct; 39(17):6747-6760. PubMed ID: 32762411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of apigenin-based biflavonoid derivatives as potential therapeutic agents against viral protease (3CLpro) of SARS-CoV-2 via molecular docking, molecular dynamics and quantum mechanics studies.
    Abdizadeh R; Hadizadeh F; Abdizadeh T
    J Biomol Struct Dyn; 2023; 41(13):5915-5945. PubMed ID: 35848354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of green tea polyphenols as novel corona virus (SARS CoV-2) main protease (Mpro) inhibitors - an
    Ghosh R; Chakraborty A; Biswas A; Chowdhuri S
    J Biomol Struct Dyn; 2021 Aug; 39(12):4362-4374. PubMed ID: 32568613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SAR, Molecular Docking and Molecular Dynamic Simulation of Natural Inhibitors against SARS-CoV-2 Mpro Spike Protein.
    Salamat A; Kosar N; Mohyuddin A; Imran M; Zahid MN; Mahmood T
    Molecules; 2024 Mar; 29(5):. PubMed ID: 38474656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants -
    Shree P; Mishra P; Selvaraj C; Singh SK; Chaube R; Garg N; Tripathi YB
    J Biomol Struct Dyn; 2022 Jan; 40(1):190-203. PubMed ID: 32851919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 proteases Mpro and PLpro: Design of inhibitors with predicted high potency and low mammalian toxicity using artificial neural networks, ligand-protein docking, molecular dynamics simulations, and ADMET calculations.
    Tumskiy RS; Tumskaia AV; Klochkova IN; Richardson RJ
    Comput Biol Med; 2023 Feb; 153():106449. PubMed ID: 36586228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statine-based peptidomimetic compounds as inhibitors for SARS-CoV-2 main protease (SARS-CoV‑2 Mpro).
    Azevedo PHRA; Camargo PG; Constant LEC; Costa SDS; Silva CS; Rosa AS; Souza DDC; Tucci AR; Ferreira VNS; Oliveira TKF; Borba NRR; Rodrigues CR; Albuquerque MG; Dias LRS; Garrett R; Miranda MD; Allonso D; Lima CHDS; Muri EMF
    Sci Rep; 2024 Apr; 14(1):8991. PubMed ID: 38637583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.